BATF/RORgt/IL-17 Axis as a Therapeutic Target in Systemic Lupus Erythematosus: Integrative Bioinformatics and In Vivo Validation of Langchuangding Combined with Prednisone
Review of Communication Research · 16.06.2026 · 89
DOI: 10.52152/fh9183 ↗Kurz gefasst
Fachartikel in der Zeitschrift Review of Communication Research, online erschienen am 16.06.2026. Verfasst von Zhaochun He und 8 weiteren Autor:innen.
Abstract (Originalsprache)
Background
Systemic lupus erythematosus (SLE) is a highly heterogeneous autoimmune disease characterized by aberrant Th17/Treg balance and autoantibody production. While glucocorticoids remain the cornerstone of treatment, their long-term adverse effects necessitate the development of steroid-sparing agents. The basic leucine zipper transcription factor ATF-like (BATF) serves as an essential pioneer factor for Th17 differentiation, yet its precise therapeutic potential in SLE remains underexplored. This study aims to validate the BATF/RORgt/IL-17 axis as a critical therapeutic target in SLE through integrative bioinformatics analysis of human cohorts and in vivo experimental validation using a combined regimen of Traditional Chinese Medicine (Langchuangding, LCD) and Prednisone.
Methods
Transcriptomic profiles of peripheral blood mononuclear cells (PBMCs) from 61 SLE patients and 20 healthy controls (HC) were retrieved from the Gene Expression Omnibus (GEO: GSE50772). Differentially expressed genes (DEGs) and immune pathway signatures were analyzed. For in vivo validation, 40 female MRL/lpr mice (SLE model) and 10 normal Kunming mice were randomly divided into five groups. Over a 10-week intervention, body weight and organ indices were monitored. The mRNA and protein expression levels of BATF, RORgt (Rorc), and IL-17 in renal tissues were quantified using qPCR and ELISA. Serum autoantibodies (ANA, anti-dsDNA, anti-Sm-DNA) were also measured.
Results
Bioinformatics analysis revealed significant upregulation of BCL6 and IL10 in SLE PBMCs, alongside a global interferon signature, establishing a pronounced systemic inflammatory state. In MRL/lpr mice, the Model group exhibited severe splenomegaly, elevated autoantibodies, and robust overexpression of renal BATF, RORgt, and IL-17. The Combined therapy (LCD + Prednisone) demonstrated superior efficacy, significantly attenuating body weight loss, normalizing spleen indices, and drastically suppressing the BATF/RORgt/IL-17 cascade at both transcriptional and translational levels (p < 0.001 vs. Model). Serum ANA, anti-dsDNA, and anti-Sm-DNA levels were also maximally reduced in the Combined group.
Conclusion
The BATF/RORgt/IL-17 axis is a pivotal pathogenic driver in SLE, bridging epigenetic chromatin remodeling with downstream Th17-mediated autoimmunity. The synergistic application of LCD and Prednisone effectively dismantles this axis, offering a promising steroid-sparing, individualized therapeutic strategy for SLE management.
Zitieren
APA
He, Z., Shao, Y., Chen, X., Xie, Z., Chen, K., Yang, K., Wang, X., Chen, Y., & Li, Z. (2026). BATF/RORgt/IL-17 Axis as a Therapeutic Target in Systemic Lupus Erythematosus: Integrative Bioinformatics and In Vivo Validation of Langchuangding Combined with Prednisone. Review of Communication Research, 89. https://doi.org/10.52152/fh9183
Vancouver
He Z, Shao Y, Chen X, Xie Z, Chen K, Yang K, et al. BATF/RORgt/IL-17 Axis as a Therapeutic Target in Systemic Lupus Erythematosus: Integrative Bioinformatics and In Vivo Validation of Langchuangding Combined with Prednisone. Review of Communication Research. 2026;89. doi:10.52152/fh9183
BibTeX
@article{He2026,
author = {He, Zhaochun and Shao, Ying and Chen, Xia and Xie, Zhimin and Chen, Keming and Yang, Kepeng and Wang, Xinchang and Chen, Yanhong and Li, Zhengfu},
title = {BATF/RORgt/IL-17 Axis as a Therapeutic Target in Systemic Lupus Erythematosus: Integrative Bioinformatics and In Vivo Validation of Langchuangding Combined with Prednisone},
journal = {Review of Communication Research},
year = {2026},
volume = {89},
doi = {10.52152/fh9183}
}
EUVIMED